Model input parameters for a Monte Carlo simulation of HCV.

S.D. = standard deviation; PY = person-year; PEG = pegylated interferon; RBV = ribavirin; TPV = telaprevir; SVR = sustained virologic response; ICM = integrated case management; IFN = interferon.
aThe lifetime probability of linking to HCV care upon receipt of a positive antibody result is 66%.
bIn the interferon-free scenario, we assumed that 54% of those linked to care would initiate therapy.
cCosts varied as a function of age and sex.
dIncludes the cost of a RNA confirmatory test and a nursing visit.
entervention costs are presented on a per participant basis, assuming that the participant completes the entire intervention. During the simulation, participants accrued costs on a monthly basis. If the participant was lost to follow-up, or otherwise withdrew from care before the end of the intervention, then that patient stopped accruing intervention costs at the time of being lost (see Appendix S1 for details).
fTreatment visit costs are higher in the first month compared to other months.
g13% of patients received a reduced weekly dose of 135 mcg in response to non-treatment ending neutropenia [45].
hRBV dose was a function of genotype (genotype 1 = 1,200 mg/day; genotype 2 or 3 = 800 mg/day). In addition, 36% of patients on triple therapy and 17% on dual therapy were treated with reduced dose RBV = 600 mg/day in response to non-treatment ending anemia [45].
iOnly patients with genotype 1 receive TPV for treatment months 1–3.
j13% of patients developed non-treatment ending neutropenia (absolute neutrophil count <750/ml) and received filgrastim 300 mcg/two times weekly [45].
kOnly patients with genotype 1 treated with PEG/RBV/TPV therapy received 150g/month for treating mild rash (28% during the first 3 months of therapy) [45].
lThe range reflects the fact that some patients were treated for 6 months, while those without rapid virologic response were treated for 12 months.
mReflects lower quality of life for individuals with HCV risk-factors such as substance use.
nThis utility weight was multiplied by an individual’s health state utility during the months that a patient was receiving HCV therapy without major toxicity. For example, a patient with HCV and mild to moderate fibrosis who underwent HCV treatment had a utility = 0.801 (0.90×0.89) during the months that (s)he was on medications.
oThis utility “toll” was subtracted from a patient’s health state utility during the month of a major toxicity event.